101
|
Cibulski SP, Mourglia-Ettlin G, Teixeira TF, Quirici L, Roehe PM, Ferreira F, Silveira F. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake. Vaccine 2016; 34:1162-71. [PMID: 26826546 DOI: 10.1016/j.vaccine.2016.01.029] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 12/15/2015] [Accepted: 01/17/2016] [Indexed: 12/20/2022]
Abstract
In the last decades, significant efforts have been dedicated to the search for novel vaccine adjuvants. In this regard, saponins and its formulations as "immunostimulating complexes" (ISCOMs) have shown to be capable of stimulating potent humoral and cellular immune responses, enhanced cytokine production and activation of cytotoxic T cells. The immunological activity of ISCOMs formulated with a saponin fraction extracted from Quillaja brasiliensis (QB-90 fraction) as an alternative to classical ISCOMs based on Quil A(®) (IQA) is presented here. The ISCOMs prepared with QB-90, named IQB-90, typically consist of 40-50 nm, spherical, cage-like particles, built up by QB-90, cholesterol, phospholipids and antigen (ovalbumin, OVA). These nanoparticles were efficiently uptaken in vitro by murine bone marrow-derived dendritic cells. Subcutaneously inoculated IQB-90 induced strong serum antibody responses encompassing specific IgG1 and IgG2a, robust DTH reactions, significant T cell proliferation and increases in Th1 (IFN-γ and IL-2) cytokine responses. Intranasally delivered IQB-90 elicited serum IgG and IgG1, and mucosal IgA responses at distal systemic sites (nasal passages, large intestine and vaginal lumen). These results indicate that IQB-90 is a promising alternative to classic ISCOMs as vaccine adjuvants, capable of enhancing humoral and cellular immunity to levels comparable to those induced by ISCOMs manufactured with Quillaja saponaria saponins.
Collapse
Affiliation(s)
- Samuel Paulo Cibulski
- FEPAGRO Saúde Animal, Instituto de Pesquisas Veterinárias Desidério Finamor, Laboratório de Virologia, Eldorado do Sul, RS, Brazil; Departamento de Microbiologia Imunologia e Parasitologia, Laboratório de Virologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Gustavo Mourglia-Ettlin
- Cátedra de Inmunología, Departamento de Biociencias, Facultad de Ciencias/Química, Universidad de la República (UdelaR), Av. Alfredo Navarro 3051, Montevideo CP. 11600, Uruguay
| | - Thais Fumaco Teixeira
- FEPAGRO Saúde Animal, Instituto de Pesquisas Veterinárias Desidério Finamor, Laboratório de Virologia, Eldorado do Sul, RS, Brazil
| | - Lenora Quirici
- Laboratorio de Carbohidratos y Glicoconjugados, Departamento de Desarrollo Biotecnológico, Facultad de Medicina. Universidad de la República (UdelaR), Av. Alfredo Navarro 3051, Montevideo CP. 11600, Uruguay
| | - Paulo Michel Roehe
- Departamento de Microbiologia Imunologia e Parasitologia, Laboratório de Virologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Fernando Ferreira
- Laboratorio de Carbohidratos y Glicoconjugados, Departamento de Desarrollo Biotecnológico, Facultad de Medicina, Departamento de Química Orgánica, Facultad de Química, Universidad de la República (UdelaR), Av. Alfredo Navarro 3051, Montevideo CP. 11600, Uruguay
| | - Fernando Silveira
- Laboratorio de Carbohidratos y Glicoconjugados, Departamento de Desarrollo Biotecnológico, Facultad de Medicina. Universidad de la República (UdelaR), Av. Alfredo Navarro 3051, Montevideo CP. 11600, Uruguay.
| |
Collapse
|
102
|
Walkowicz WE, Fernández-Tejada A, George C, Corzana F, Jiménez-Barbero J, Ragupathi G, Tan DS, Gin DY. Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities. Chem Sci 2016; 7:2371-2380. [PMID: 27014435 PMCID: PMC4800320 DOI: 10.1039/c5sc02978c] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
A mouse vaccination model and molecular dynamics studies reveal characteristic conformations of active QS-21 variants.
Immunological adjuvants such as the saponin natural product QS-21 help stimulate the immune response to co-administered antigens and have become increasingly important in the development of prophylactic and therapeutic vaccines. However, clinical use of QS-21 is encumbered by chemical instability, dose-limiting toxicity, and low-yielding purification from the natural source. Previous studies of structure–activity relationships in the four structural domains of QS-21 have led to simplified, chemically stable variants that retain potent adjuvant activity and low toxicity in mouse vaccination models. However, modification of the central glycosyl ester linkage has not yet been explored. Herein, we describe the design, synthesis, immunologic evaluation, and molecular dynamics analysis of a series of novel QS-21 variants with different linker lengths, stereochemistry, and flexibility to investigate the role of this linkage in saponin adjuvant activity and conformation. Despite relatively conservative structural modifications, these variants exhibit striking differences in in vivo adjuvant activity that correlate with specific conformational preferences. These results highlight the junction of the triterpene and linear oligosaccharide domains as playing a critical role in the immunoadjuvant activity of the Quillaja saponins and also suggest a mechanism of action involving interaction with a discrete macromolecular target, in contrast to the non-specific mechanisms of emulsion-based adjuvants.
Collapse
Affiliation(s)
- William E Walkowicz
- Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, 1275 York Avenue, New York, NY 10065, United States
| | - Alberto Fernández-Tejada
- Chemical Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Chemical & Physical Biology, Center for Biological Research, CIB-CSIC, 28040 Madrid, Spain
| | - Constantine George
- Melanoma & Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
| | - Francisco Corzana
- Department of Chemistry, University of La Rioja, 26006 Logroño, Spain
| | - Jesús Jiménez-Barbero
- Chemical & Physical Biology, Center for Biological Research, CIB-CSIC, 28040 Madrid, Spain; Structural Biology, Center for Cooperative Research, CIC-bioGUNE, 48160 Derio-Bizkaia, Spain; Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
| | - Govind Ragupathi
- Melanoma & Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
| | - Derek S Tan
- Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, 1275 York Avenue, New York, NY 10065, United States; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
| | - David Y Gin
- Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, 1275 York Avenue, New York, NY 10065, United States; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
| |
Collapse
|
103
|
Orczyk M, Wojciechowski K. Comparison of the effect of two Quillaja bark saponin extracts on DPPC and DPPC/cholesterol Langmuir monolayers. Colloids Surf B Biointerfaces 2015; 136:291-9. [DOI: 10.1016/j.colsurfb.2015.09.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Revised: 09/09/2015] [Accepted: 09/10/2015] [Indexed: 11/28/2022]
|
104
|
Greatrex BW, Daines AM, Hook S, Lenz DH, McBurney W, Rades T, Rendle PM. Synthesis, Formulation, and Adjuvanticity of Monodesmosidic Saponins with Olenanolic Acid, Hederagenin and Gypsogenin Aglycones, and some C-28 Ester Derivatives. ChemistryOpen 2015; 4:740-55. [PMID: 27308200 PMCID: PMC4906508 DOI: 10.1002/open.201500149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Revised: 08/20/2015] [Indexed: 11/06/2022] Open
Abstract
In an attempt to discover a new synthetic vaccine adjuvant, the glycosylation of hederagenin, gypsogenin, and oleanolic acid acceptors with di- and trisaccharide donors to generate a range of mimics of natural product QS-21 was carried out. The saponins were formulated with phosphatidylcholine and cholesterol, and the structures analyzed by transmission electron microscopy. 3-O-(Manp(1→3)Glcp)hederagenin was found to produce numerous ring-like micelles when formulated, while C-28 choline ester derivatives preferred self-assembly and did not interact with the liposomes. When alone and in the presence of cholesterol and phospholipid, the choline ester derivatives produced nanocrystalline rods or helical micelles. The effects of modifying sugar stereochemistry and the aglycone on the immunostimulatory effects of the saponins was then evaluated using the activation markers MHC class II and CD86 in murine bone marrow dendritic cells. The most active saponin, 3-O-(Manp(1→3)Glcp)hederagenin, was stimulatory at high concentrations in cell culture, but this did not translate to strong responses in vivo.
Collapse
Affiliation(s)
- Ben W. Greatrex
- Ferrier Research InstituteVictoria University of WellingtonGracefield RdLower Hutt5010New Zealand
- School of Science & TechnologyUniversity of New EnglandArmidaleNSW2351Australia
| | - Alison M. Daines
- Ferrier Research InstituteVictoria University of WellingtonGracefield RdLower Hutt5010New Zealand
| | - Sarah Hook
- School of PharmacyUniversity of OtagoDunedin9016New Zealand
| | - Dirk H. Lenz
- Ferrier Research InstituteVictoria University of WellingtonGracefield RdLower Hutt5010New Zealand
| | | | - Thomas Rades
- School of PharmacyUniversity of OtagoDunedin9016New Zealand
| | - Phillip M. Rendle
- Ferrier Research InstituteVictoria University of WellingtonGracefield RdLower Hutt5010New Zealand
| |
Collapse
|
105
|
Marty-Roix R, Vladimer GI, Pouliot K, Weng D, Buglione-Corbett R, West K, MacMicking JD, Chee JD, Wang S, Lu S, Lien E. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J Biol Chem 2015; 291:1123-36. [PMID: 26555265 DOI: 10.1074/jbc.m115.683011] [Citation(s) in RCA: 133] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Indexed: 01/09/2023] Open
Abstract
Many immunostimulants act as vaccine adjuvants via activation of the innate immune system, although in many cases it is unclear which specific molecules contribute to the stimulatory activity. QS-21 is a defined, highly purified, and soluble saponin adjuvant currently used in licensed and exploratory vaccines, including vaccines against malaria, cancer, and HIV-1. However, little is known about the mechanisms of cellular activation induced by QS-21. We observed QS-21 to elicit caspase-1-dependent IL-1β and IL-18 release in antigen-presenting cells such as macrophages and dendritic cells when co-stimulated with the TLR4-agonist adjuvant monophosphoryl lipid A. Furthermore, our data suggest that the ASC-NLRP3 inflammasome is responsible for QS-21-induced IL-1β/IL-18 release. At higher concentrations, QS-21 induced macrophage and dendritic cell death in a caspase-1-, ASC-, and NLRP3-independent manner, whereas the presence of cholesterol rescued cell viability. A nanoparticulate adjuvant that contains QS-21 as part of a heterogeneous mixture of saponins also induced IL-1β in an NLRP3-dependent manner. Interestingly, despite the role NLRP3 plays for cellular activation in vitro, NLRP3-deficient mice immunized with HIV-1 gp120 and QS-21 showed significantly higher levels of Th1 and Th2 antigen-specific T cell responses and increased IgG1 and IgG2c compared with wild type controls. Thus, we have identified QS-21 as a nonparticulate single molecular saponin that activates the NLRP3 inflammasome, but this signaling pathway may contribute to decreased antigen-specific responses in vivo.
Collapse
Affiliation(s)
- Robyn Marty-Roix
- From the Program in Innate Immunity, Division of Infectious Diseases and Immunology and
| | - Gregory I Vladimer
- From the Program in Innate Immunity, Division of Infectious Diseases and Immunology and
| | - Kimberly Pouliot
- From the Program in Innate Immunity, Division of Infectious Diseases and Immunology and
| | - Dan Weng
- From the Program in Innate Immunity, Division of Infectious Diseases and Immunology and
| | - Rachel Buglione-Corbett
- the Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School Worcester, Massachusetts 01605
| | - Kim West
- the Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School Worcester, Massachusetts 01605
| | - John D MacMicking
- the Department of Microbial Pathogenesis, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, and
| | - Jonathan D Chee
- the Department of Microbial Pathogenesis, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, and
| | - Shixia Wang
- the Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School Worcester, Massachusetts 01605
| | - Shan Lu
- the Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School Worcester, Massachusetts 01605
| | - Egil Lien
- From the Program in Innate Immunity, Division of Infectious Diseases and Immunology and the Centre of Molecular Inflammation Research, Department of Cancer and Molecular Medicine, NTNU, 7491 Trondheim, Norway
| |
Collapse
|
106
|
Fernández-Tejada A, Tan DS, Gin DY. Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants. Chem Commun (Camb) 2015; 51:13949-13952. [PMID: 26243268 PMCID: PMC4643164 DOI: 10.1039/c5cc05244k] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We describe a new, versatile synthetic approach to Quillaja saponin variants based on the natural product immunoadjuvant QS-21. This modular, divergent strategy provides efficient access to linear oligosaccharide domain variants with modified sugars and regiochemistries. This new synthetic approach opens the door to the rapid generation of diverse analogues to identify novel saponin adjuvants with improved synthetic accessibility.
Collapse
Affiliation(s)
- Alberto Fernández-Tejada
- Chemical Biology Program, Memorial Sloan Kettering Cancer Center, 1 275 York Avenue, New York, NY 10065, USA.
| | - Derek S Tan
- Chemical Biology Program, Memorial Sloan Kettering Cancer Center, 1 275 York Avenue, New York, NY 10065, USA.
- Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1 275 York Avenue, New York, NY 10065, USA.
| | - David Y Gin
- Chemical Biology Program, Memorial Sloan Kettering Cancer Center, 1 275 York Avenue, New York, NY 10065, USA.
- Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1 275 York Avenue, New York, NY 10065, USA.
| |
Collapse
|
107
|
Hu J, Qiu L, Wang X, Zou X, Lu M, Yin J. Carbohydrate-based vaccine adjuvants - discovery and development. Expert Opin Drug Discov 2015; 10:1133-44. [PMID: 26372693 DOI: 10.1517/17460441.2015.1067198] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
INTRODUCTION The addition of a suitable adjuvant to a vaccine can generate significant effective adaptive immune responses. There is an urgent need for the development of novel po7tent and safe adjuvants for human vaccines. Carbohydrate molecules are promising adjuvants for human vaccines due to their high biocompatibility and good tolerability in vivo. AREAS COVERED The present review covers a few promising carbohydrate-based adjuvants, lipopolysaccharide, trehalose-6,6'-dibehenate, QS-21 and inulin as examples, which have been extensively studied in human vaccines in a number of preclinical and clinical studies. The authors discuss the current status, applications and strategies of development of each adjuvant and different adjuvant formulation systems. This information gives insight regarding the exciting prospect in the field of carbohydrate-based adjuvant research. EXPERT OPINION Carbohydrate-based adjuvants are promising candidates as an alternative to the Alum salts for human vaccines development. Furthermore, combining two or more adjuvants in one formulation is one of the effective strategies in adjuvant development. However, further research efforts are needed to study and develop novel adjuvants systems, which can be more stable, potent and safe. The development of synthetic carbohydrate chemistry can improve the study of carbohydrate-based adjuvants.
Collapse
Affiliation(s)
- Jing Hu
- a 1 Jiangnan University, Wuxi Medical School , Lihu Avenue 1800, 214122, Wuxi, China
| | - Liying Qiu
- a 1 Jiangnan University, Wuxi Medical School , Lihu Avenue 1800, 214122, Wuxi, China
| | - Xiaoli Wang
- b 2 Jiangnan University, The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology , Lihu Avenue 1800, 214122, Wuxi, China +86 51 085 328 229 ; +86 51 085 328 229 ;
| | - Xiaopeng Zou
- b 2 Jiangnan University, The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology , Lihu Avenue 1800, 214122, Wuxi, China +86 51 085 328 229 ; +86 51 085 328 229 ;
| | - Mengji Lu
- c 3 University Hospital Essen, Institute of Virology , Hufelandstr, 55, 45122 Essen, Germany +49 2 017 233 530 ; +49 2 017 235 929 ;
| | - Jian Yin
- b 2 Jiangnan University, The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology , Lihu Avenue 1800, 214122, Wuxi, China +86 51 085 328 229 ; +86 51 085 328 229 ;
| |
Collapse
|
108
|
Affiliation(s)
- Daming Zhu
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
| | - Wenbin Tuo
- Animal Parasitic Diseases Laboratory, Agricultural Research Service, USDA, Beltsville, MD 20705, USA
| |
Collapse
|
109
|
Noh HJ, Chowdhury MYE, Cho S, Kim JH, Park HS, Kim CJ, Poo H, Sung MH, Lee JS, Lim YT. Programming of Influenza Vaccine Broadness and Persistence by Mucoadhesive Polymer-Based Adjuvant Systems. THE JOURNAL OF IMMUNOLOGY 2015. [PMID: 26216889 DOI: 10.4049/jimmunol.1500492] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The development of an anti-influenza vaccine with the potential for cross-protection against seasonal drift variants as well as occasionally emerging reassortant viruses is essential. In this study, we successfully generated a novel anti-influenza vaccine system combining conserved matrix protein 2 (sM2) and stalk domain of hemagglutinin (HA2) fusion protein (sM2HA2) and poly-γ-glutamic acid (γ-PGA)-based vaccine adjuvant systems that can act as a mucoadhesive delivery vehicle of sM2HA2 as well as a robust strategy for the incorporation of hydrophobic immunostimulatory 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and QS21. Intranasal coadministration of sM2HA2 and the combination adjuvant γ-PGA/MPL/QS21 (CA-PMQ) was able to induce a high degree of protective mucosal, systemic, and cell-mediated immune responses. The sM2HA2/CA-PMQ immunization was able to prevent disease symptoms, confering complete protection against lethal infection with divergent influenza subtypes (H5N1, H1N1, H5N2, H7N3, and H9N2) that lasted for at least 6 mo. Therefore, our data suggest that mucosal administration of sM2HA2 in combination with CA-PMQ could be a potent strategy for a broad cross-protective influenza vaccine, and CA-PMQ as a mucosal adjuvant could be used for effective mucosal vaccines.
Collapse
Affiliation(s)
- Hyun Jong Noh
- Department of Chemical Engineering, Sungkyunkwan University Advanced Institute of Nanotechnology, Suwon 440-746, South Korea
| | - Mohammed Y E Chowdhury
- College of Veterinary Medicine (BK21 Plus Program), Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon 305-764, South Korea; Faculty of Veterinary Medicine, Chittagong Veterinary and Animal Sciences University, Chittagong 4202, Bangladesh
| | - Seonghun Cho
- College of Veterinary Medicine (BK21 Plus Program), Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon 305-764, South Korea
| | - Jae-Hoon Kim
- College of Veterinary Medicine (BK21 Plus Program), Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon 305-764, South Korea
| | - Hye Sun Park
- Korea Basic Science Institute, Chungbuk 363-883, South Korea
| | - Chul-Joong Kim
- College of Veterinary Medicine (BK21 Plus Program), Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon 305-764, South Korea
| | - Haryoung Poo
- Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, South Korea; and
| | - Moon-Hee Sung
- Department of Advanced Fermentation Fusion Science and Technology, Kookmin University, Seoul 136-702, South Korea
| | - Jong-Soo Lee
- College of Veterinary Medicine (BK21 Plus Program), Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon 305-764, South Korea;
| | - Yong Taik Lim
- Department of Chemical Engineering, Sungkyunkwan University Advanced Institute of Nanotechnology, Suwon 440-746, South Korea;
| |
Collapse
|
110
|
Zhurov KO, Menin L, Di Franco T, Tsybin YO. A Functional Group Approach for Prediction of APPI Response of Organic Synthetic Targets. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2015; 26:1221-1232. [PMID: 25895888 DOI: 10.1007/s13361-015-1116-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Revised: 02/13/2015] [Accepted: 02/13/2015] [Indexed: 06/04/2023]
Abstract
Atmospheric pressure photoionization (APPI) is a technique of choice for ionization of non-polar molecules in mass spectrometry (MS). Reported APPI-based studies tend to focus on a selected compound class, which may contain a variety of functional groups. These studies demonstrate that APPI response frequently differs substantially, indicating a certain dependence on the functional group present. Although this dependence could be employed for APPI response prediction, its systematic use is currently absent. Here, we apply APPI MS to a judiciously-compiled set of 63 compounds containing a number of diverse functional groups commonly utilized in synthesis, reactive functional groups, as well as those containing boron and silicon. Based on the outcome of APPI MS of these compounds, we propose and evaluate a simple guideline to estimate the APPI response for a novel compound, the key properties of which have not been characterized in the gas phase. Briefly, we first identify key functional groups in the compound and gather knowledge on the known ionization energies from the smallest analogues containing said functional groups. We then consider local inductive and resonance effects on said ionization energies for the compounds of interest to estimate the APPI response. Finally, application of APPI MS to compounds of interest considered herein demonstrated extended upper mass ionization limit of 3.5 kDa for non-polymeric compounds.
Collapse
Affiliation(s)
- Konstantin O Zhurov
- Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne, 1015, Lausanne, Switzerland
| | | | | | | |
Collapse
|
111
|
Boubaker G, Hemphill A, Huber CO, Spiliotis M, Babba H, Gottstein B. Prevention and Immunotherapy of Secondary Murine Alveolar Echinococcosis Employing Recombinant EmP29 Antigen. PLoS Negl Trop Dis 2015; 9:e0003795. [PMID: 26053794 PMCID: PMC4460070 DOI: 10.1371/journal.pntd.0003795] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Accepted: 04/28/2015] [Indexed: 12/13/2022] Open
Abstract
Alveolar echinococcosis (AE) is caused by infection with the larval stage of the tapeworm Echinococcus multilocularis. An increasing understanding of immunological events that account for the metacestode survival in human and murine AE infection prompted us to undertake explorative experiments tackling the potential of novel preventive and/or immunotherapeutic measures. In this study, the immunoprotective and immunotherapeutic ability of recombinant EmP29 antigen (rEmP29) was assessed in mice that were intraperitoneally infected with E. multilocularis metacestodes. For vaccination, three intraperitoneal injections with 20μg rEmP29 emulsified in saponin adjuvants were applied over 6 weeks. 2 weeks after the last boost, mice were infected, and at 90 days post-infection, rEmP29-vaccinated mice exhibited a median parasite weight that was reduced by 75% and 59% when compared to NaCl- or saponin–treated control mice, respectively. For immunotherapeutical application, the rEmP29 (20μg) vaccine was administered to experimentally infected mice, starting at 1 month post-infection, three times with 2 weeks intervals. Mice undergoing rEmP29 immunotherapy exhibited a median parasite load that was reduced by 53% and 49% when compared to NaCl- and saponin–treated control mice, respectively. Upon analysis of spleen cells, both, vaccination and treatment with rEmP29, resulted in low ratios of Th2/Th1 (IL-4/IFN-γ) cytokine mRNA and low levels of mRNA coding for IL-10 and IL-2. These results suggest that reduction of the immunosuppressive environment takes place in vaccinated as well as immunotreated mice, and a shift towards a Th1 type of immune response may be responsible for the observed increased restriction of parasite growth. The present study provides the first evidence that active immunotherapy may present a sustainable route for the control of AE. Current medical management of AE that relies on surgery and continuous benzimidazole administration is of limited effectiveness. Therefore, alternative preventive and therapeutic tools need to be explored. Here, we demonstrate that vaccination with recombinant antigen EmP29 (rEmP29), prior or after secondary infection of BALB/c mice, resulted in a significant reduction of the median parasite weight when compared to different control groups. We then characterized the transcription level of splenic IL-4 and IFN-γ cytokines as hallmarks for AE-anti-protective humoral immune reaction (Th2) and for AE-effective (restrictive) cellular response (Th1), respectively. Results revealed that vaccinated mice in pre- or post-infection situation exhibited the lowest IL-4/IFN-γ mRNA ratios. In addition, those groups showed also significantly low levels of IL-10-encoding mRNA coding (immunosuppressive cytokine), as well as IL-2. These findings suggest that reduction of parasite load in rEmP29-vaccinated mice (in pre- or post-infection status) might be triggered by a decline of the immunosuppressive environment and a change of the host immune reaction towards a Th1-re-oriented cell-mediated immune defense. A similar non-specific effect appears also to be yielded by the immunostimulating adjuvants. This study provides the first insight into the potential benefits of antigen-specific immunotherapy as new treatment option of AE.
Collapse
Affiliation(s)
- Ghalia Boubaker
- Institute of Parasitology, University of Bern, Bern, Switzerland
- Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
- Faculty of Pharmacy, Department of Clinical Biology B, Laboratory of Medical and Molecular Parasitology–Mycology (LR12ES08), University of Monastir, Monastir, Tunisia
| | - Andrew Hemphill
- Institute of Parasitology, University of Bern, Bern, Switzerland
| | | | - Markus Spiliotis
- Institute of Parasitology, University of Bern, Bern, Switzerland
| | - Hamouda Babba
- Faculty of Pharmacy, Department of Clinical Biology B, Laboratory of Medical and Molecular Parasitology–Mycology (LR12ES08), University of Monastir, Monastir, Tunisia
| | - Bruno Gottstein
- Institute of Parasitology, University of Bern, Bern, Switzerland
- * E-mail:
| |
Collapse
|
112
|
Fernández-Tejada A, Cañada FJ, Jiménez-Barbero J. Glycans in Medicinal Chemistry: An Underexploited Resource. ChemMedChem 2015; 10:1291-5. [PMID: 25974358 DOI: 10.1002/cmdc.201500107] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Indexed: 11/05/2022]
Abstract
The biological relevance of glycans as mediators of key physiological processes, including disease-related mechanisms, makes them attractive targets for a wide range of medical applications. Despite their important biological roles, especially as molecular recognition elements, carbohydrates have not been fully exploited as therapeutics mainly due to the scarcity of structure-activity correlations and their non-drug-like properties. A more detailed understanding of the complex carbohydrate structures and their associated functions should contribute to the development of new glycan-based pharmaceuticals. Recent significant progress in oligosaccharide synthesis and chemical glycobiology has renewed the interest of the medicinal chemistry community in carbohydrates. This promises to increase our possibilities to harness them in drug discovery efforts for the development of new and more effective, synthetic glycan-based therapeutics and vaccines.
Collapse
Affiliation(s)
- Alberto Fernández-Tejada
- Chemical and Physical Biology, Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, 28040 Madrid (Spain).
| | - F Javier Cañada
- Chemical and Physical Biology, Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, 28040 Madrid (Spain)
| | - Jesús Jiménez-Barbero
- CIC bioGUNE: Center for Cooperative Research in Biosciences, Bizkaia Technology Park, 48160 Derio (Spain). .,Ikerbasque, Basque Foundation for Science, María López de Haro 13, 48009 Bilbao (Spain).
| |
Collapse
|
113
|
Yin Z, Huang X. Boosting Humoral Immune Responses to Tumor-associated Carbohydrate Antigens with Virus-like Particles. CARBOHYDRATES IN DRUG DESIGN AND DISCOVERY 2015. [DOI: 10.1039/9781849739993-00132] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The development of carbohydrate-based anticancer vaccines is an attractive approach towards the prevention and treatment of cancer. The weak immunogenicity of carbohydrate antigens and tolerance by the immune system are major obstacles towards the design of effective cancer vaccines. Recently, virus-like particles have been shown to be a promising platform to overcome the aforementioned difficulties. In this chapter, we provide an overview on the structural and immunological features of virus-like particles in eliciting anti-carbohydrate antibody responses. The immuno-potentiating activities of several virus-like particle systems are compared, and insights into critical factors of virus-like particles that help shape the anti-carbohydrate responses are discussed.
Collapse
Affiliation(s)
- Zhaojun Yin
- Department of Chemistry, Chemistry Building, 578 S. Shaw Lane, Michigan State University East Lansing, MI 48824 USA
| | - Xuefei Huang
- Department of Chemistry, Chemistry Building, 578 S. Shaw Lane, Michigan State University East Lansing, MI 48824 USA
| |
Collapse
|
114
|
Zimmermann S, Lepenies B. Glycans as Vaccine Antigens and Adjuvants: Immunological Considerations. Methods Mol Biol 2015; 1331:11-26. [PMID: 26169732 DOI: 10.1007/978-1-4939-2874-3_2] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Carbohydrates can be found on the cell surface of nearly every cell ranging from bacteria to fungi right up to mammalian cells. Carbohydrates and their interactions with carbohydrate-binding proteins play crucial roles in multiple biological processes including immunity, homeostasis, cellular communication, cell migration, and the regulation of serum glycoprotein levels. In the last decades, the interest in exploiting the biological activity of glycans as vaccine components has considerably increased. On the one hand, carbohydrates display epitopes to generate protective antibodies against pathogen-derived cell wall structures and on the other hand, glycans have the potential to stimulate the immune system; thus they can act as potent vaccine adjuvants.An effective vaccine consists of two major components, the vaccine antigen and an adjuvant. The vaccine antigen is an original or modified part of the pathogen that causes the disease. The immune response triggered by vaccination should induce antigen-specific plasma cells secreting protective antibodies as well as the development of memory T and B cells. Carbohydrate structures on pathogens represent an important class of antigens that can activate B cells to produce protective anti-carbohydrate antibodies in adults. A major breakthrough in vaccine development was the design of conjugate vaccines that evoke protective antibody responses against encapsulated bacteria strains such as Haemophilus influenzae, Streptococcus pneumoniae, or Neisseria meningitidis in adults, but also in young children. The first part of this chapter focuses on immune responses triggered by carbohydrate-based vaccines. The second part of the chapter discusses the immunological mechanisms of carbohydrate-based adjuvants to increase the immunogenicity of vaccines.
Collapse
Affiliation(s)
- Stephanie Zimmermann
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1, 14476, Potsdam, Germany,
| | | |
Collapse
|
115
|
Fernández-Tejada A, Chea EK, George C, Gardner JR, Livingston PO, Ragupathi G, Tan DS, Gin DY. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol. Bioorg Med Chem 2014; 22:5917-23. [PMID: 25284254 PMCID: PMC4410046 DOI: 10.1016/j.bmc.2014.09.016] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2014] [Revised: 09/02/2014] [Accepted: 09/08/2014] [Indexed: 12/11/2022]
Abstract
Immunoadjuvants are used to potentiate the activity of modern subunit vaccines that are based on molecular antigens. An emerging approach involves the combination of multiple adjuvants in a single formulation to achieve optimal vaccine efficacy. Herein, to investigate such potential synergies, we synthesized novel adjuvant conjugates based on the saponin natural product QS-21 and the aldehyde tucaresol via chemoselective acylation of an amine at the terminus of the acyl chain domain in QS saponin variants. In a preclinical mouse vaccination model, these QS saponin-tucaresol conjugates induced antibody responses similar to or slightly higher than those generated with related QS saponin variants lacking the tucaresol motif. The conjugates retained potent adjuvant activity, low toxicity, and improved activity-toxicity profiles relative to QS-21 itself and induced IgG subclass profiles similar to those of QS-21, indicative of both Th1 cellular and Th2 humoral immune responses. This study opens the door to installation of other substituents at the terminus of the acyl chain domain to develop additional QS saponin conjugates with desirable immunologic properties.
Collapse
Affiliation(s)
- Alberto Fernández-Tejada
- Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
| | - Eric K Chea
- Pharmacology Graduate Program, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - Constantine George
- Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - Jeffrey R Gardner
- Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - Philip O Livingston
- Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - Govind Ragupathi
- Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
| | - Derek S Tan
- Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Pharmacology Graduate Program, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
| | - David Y Gin
- Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Pharmacology Graduate Program, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| |
Collapse
|
116
|
Sun H, He S, Shi M. Adjuvant-active fraction from Albizia julibrissin saponins improves immune responses by inducing cytokine and chemokine at the site of injection. Int Immunopharmacol 2014; 22:346-55. [DOI: 10.1016/j.intimp.2014.07.021] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 06/28/2014] [Accepted: 07/16/2014] [Indexed: 11/26/2022]
|
117
|
Bhandari P, Patel NK, Gangwal RP, Sangamwar AT, Bhutani KK. Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: Synthesis, biological evaluation and docking studies. Bioorg Med Chem Lett 2014; 24:4114-9. [DOI: 10.1016/j.bmcl.2014.07.056] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 07/07/2014] [Accepted: 07/19/2014] [Indexed: 01/11/2023]
|
118
|
Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, Garçon N, Van Mechelen M, Morel S. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. THE JOURNAL OF IMMUNOLOGY 2014; 193:1920-30. [PMID: 25024381 DOI: 10.4049/jimmunol.1400948] [Citation(s) in RCA: 183] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Adjuvant System AS01 is a liposome-based vaccine adjuvant containing 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21. AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III). Given the known immunostimulatory properties of MPL and QS-21, the objective of this study was to describe the early immune response parameters after immunization with an AS01-adjuvanted vaccine and to identify relationships with the vaccine-specific adaptive immune response. Cytokine production and innate immune cell recruitment occurred rapidly and transiently at the muscle injection site and draining lymph node postinjection, consistent with the rapid drainage of the vaccine components to the draining lymph node. The induction of Ag-specific Ab and T cell responses was dependent on the Ag being injected at the same time or within 24 h after AS01, suggesting that the early events occurring postinjection were required for these elevated adaptive responses. In the draining lymph node, after 24 h, the numbers of activated and Ag-loaded monocytes and MHCII(high) dendritic cells were higher after the injection of the AS01-adjuvanted vaccine than after Ag alone. However, only MHCII(high) dendritic cells appeared efficient at and necessary for direct Ag presentation to T cells. These data suggest that the ability of AS01 to improve adaptive immune responses, as has been demonstrated in clinical trials, is linked to a transient stimulation of the innate immune system leading to the generation of high number of efficient Ag-presenting dendritic cells.
Collapse
Affiliation(s)
| | | | | | | | - Kaat Fierens
- Vlaams Instituut voor Biotechnologie Inflammation Research Center, Ghent University, 9052 Ghent, Belgium; and
| | | | | | | | - Bernard Malissen
- Centre d'Immunologie de Marseille-Luminy, Aix-Marseille Université, INSERM U1104, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7280, 13288 Marseille cedex 9, France
| | - Bart N Lambrecht
- Vlaams Instituut voor Biotechnologie Inflammation Research Center, Ghent University, 9052 Ghent, Belgium; and
| | | | | | - Sandra Morel
- GlaxoSmithKline Vaccines, 1330 Rixensart, Belgium
| |
Collapse
|
119
|
Bissinger R, Modicano P, Alzoubi K, Honisch S, Faggio C, Abed M, Lang F. Effect of saponin on erythrocytes. Int J Hematol 2014; 100:51-9. [DOI: 10.1007/s12185-014-1605-z] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Revised: 05/20/2014] [Accepted: 05/22/2014] [Indexed: 12/22/2022]
|
120
|
Development of a minimal saponin vaccine adjuvant based on QS-21. Nat Chem 2014; 6:635-43. [PMID: 24950335 PMCID: PMC4215704 DOI: 10.1038/nchem.1963] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Accepted: 04/22/2014] [Indexed: 11/16/2022]
Abstract
Adjuvants are materials added to vaccines to enhance the immunological response to an antigen. QS-21 is a natural product adjuvant under investigation in numerous vaccine clinical trials, but its use is constrained by scarcity, toxicity, instability, and an enigmatic molecular mechanism of action. Herein, we describe the development of a minimal QS-21 analogue that decouples adjuvant activity from toxicity and provides a powerful platform for mechanistic investigations. We found that the entire branched trisaccharide domain of QS-21 is dispensable for adjuvant activity and that the C4-aldehyde substituent, previously proposed to bind covalently to an unknown cellular target, is also not required. Biodistribution studies revealed that active adjuvants were retained at the injection site and nearest draining lymph nodes preferentially compared to attenuated variants. Overall, these studies have yielded critical insights into saponin structure–function relationships, provided practical synthetic access to non-toxic adjuvants, and established a platform for detailed mechanistic studies.
Collapse
|
121
|
Wang S, Yu Y, Geng S, Wang D, Zhang L, Xie X, Wu B, Li C, Xu H, Li X, Hu Y, Zhang L, Kaether C, Wang B. A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. ALZHEIMERS RESEARCH & THERAPY 2014; 6:26. [PMID: 24987466 PMCID: PMC4075150 DOI: 10.1186/alzrt256] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Accepted: 04/07/2014] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer's disease (AD). One drawback in the past was that clinical trial approval was withheld because of speculation that the Aβ42 vaccine induces CD4(+) T cell infiltrations into the central nervous system. To reduce T-cell activation while concomitantly maintaining high anti-Aβ42 titers is a great challenge in immunology. METHODS We aimed to demonstrate that coimmunization with Aβ42 protein and expression plasmid can be beneficial in a mouse AD model and can prevent inflammation. We immunized the AD mice with the coimmunization vaccine and assessed behavior change and Aβ42 deposition. Furthermore, to determine the safety of the coimmunization vaccine, we used an induced Aβ42-EAE model to mimic the meningoencephalitis that happened in the AN-1792 vaccine clinical phase II trial and tested whether the coimmunization vaccine could ameliorate T-cell-mediated brain inflammation. RESULTS The coimmunization vaccination reduced Aβ plaques and significantly ameliorated cognitive deficit while inhibiting T-cell-mediated brain inflammation and infiltration. These studies demonstrate that the coimmunization strategy that we describe in this article can ameliorate AD pathology without notable adverse effects in mice. CONCLUSIONS A coimmunization strategy leading to the development of a safe immunotherapeutic/preventive protocol against AD in humans is warranted.
Collapse
Affiliation(s)
- Shuang Wang
- Key Laboratory of Medical Molecular Virology of MOH and MOE, Fudan University Shanghai Medical College, 131 Dong An Road, Shanghai 200032, China ; State Key Laboratory for Agro-Biotechnology and College of Biologic Sciences, China Agricultural University, 2 Yuanmingyuan West Road, Beijing 100193, China
| | - Yang Yu
- State Key Laboratory for Agro-Biotechnology and College of Biologic Sciences, China Agricultural University, 2 Yuanmingyuan West Road, Beijing 100193, China ; Present address: MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Shuang Geng
- Key Laboratory of Medical Molecular Virology of MOH and MOE, Fudan University Shanghai Medical College, 131 Dong An Road, Shanghai 200032, China
| | - Dongmei Wang
- Chinese Academy of Medical Sciences & Comparative Medical Center, 5 South Panjiayuan, Beijing 100021, China
| | - Li Zhang
- Chinese Academy of Medical Sciences & Comparative Medical Center, 5 South Panjiayuan, Beijing 100021, China
| | - Xiaoping Xie
- State Key Laboratory for Agro-Biotechnology and College of Biologic Sciences, China Agricultural University, 2 Yuanmingyuan West Road, Beijing 100193, China
| | - Bing Wu
- State Key Laboratory for Agro-Biotechnology and College of Biologic Sciences, China Agricultural University, 2 Yuanmingyuan West Road, Beijing 100193, China
| | - Chaofan Li
- Key Laboratory of Medical Molecular Virology of MOH and MOE, Fudan University Shanghai Medical College, 131 Dong An Road, Shanghai 200032, China
| | - Hanqian Xu
- State Key Laboratory for Agro-Biotechnology and College of Biologic Sciences, China Agricultural University, 2 Yuanmingyuan West Road, Beijing 100193, China
| | - Xiaolin Li
- Institute for Age Research, Fritz Lipmann Institute, Beutenbergstraße 11, Jena D-07745, Germany
| | - Yanxin Hu
- Department of Pathology, College of Veterinary Medicine, China Agricultural University, 2 Yuanmingyuan West Road, Beijing 100193, China
| | - Lianfeng Zhang
- Chinese Academy of Medical Sciences & Comparative Medical Center, 5 South Panjiayuan, Beijing 100021, China
| | - Christoph Kaether
- Institute for Age Research, Fritz Lipmann Institute, Beutenbergstraße 11, Jena D-07745, Germany
| | - Bin Wang
- Key Laboratory of Medical Molecular Virology of MOH and MOE, Fudan University Shanghai Medical College, 131 Dong An Road, Shanghai 200032, China
| |
Collapse
|
122
|
Pedebos C, Pol-Fachin L, Pons R, Teixeira CV, Verli H. Atomic model and micelle dynamics of QS-21 saponin. Molecules 2014; 19:3744-60. [PMID: 24662086 PMCID: PMC6271892 DOI: 10.3390/molecules19033744] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Revised: 02/28/2014] [Accepted: 03/05/2014] [Indexed: 11/16/2022] Open
Abstract
QS-21 is a saponin extracted from Quillaja saponaria, widely investigated as a vaccine immunoadjuvant. However, QS-21 use is mainly limited by its chemical instability, significant variety in molecular composition and low tolerance dose in mammals. Also, this compound tends to form micelles in a concentration-dependent manner. Here, we aimed to characterize its conformation and the process of micelle formation, both experimentally and computationally. Therefore, molecular dynamics (MD) simulations were performed in systems containing different numbers of QS-21 molecules in aqueous solution, in order to evaluate the spontaneous micelle formation. The applied methodology allowed the generation of micelles whose sizes were shown to be in high agreement with small-angle X-ray scattering (SAXS). Furthermore, the ester linkage between fucose and acyl chain was less solvated in the micellar form, suggesting a reduction in hydrolysis. This is the first atomistic interpretation of previous experimental data, the first micellar characterization of saponin micelles by SAXS and first tridimensional model of a micelle constituted of saponins, contributing to the understanding of the molecular basis of these compounds.
Collapse
Affiliation(s)
- Conrado Pedebos
- Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Av Bento Gonçalves 9500, CP 15005, Porto Alegre 91500-970, RS, Brazil.
| | - Laércio Pol-Fachin
- Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Av Bento Gonçalves 9500, CP 15005, Porto Alegre 91500-970, RS, Brazil.
| | - Ramon Pons
- Departament de Tecnologia Química i de Tensioactius, Institut de Química Avançada de Catalunya, IQAC_CSIC, Jordi Girona, 18-26, Barcelona 08034, Spain.
| | - Cilâine V Teixeira
- Instituto de Física, Universidade Federal do Rio Grande do Sul, CP15051, Porto Alegre 91501-970, RS, Brazil.
| | - Hugo Verli
- Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Av Bento Gonçalves 9500, CP 15005, Porto Alegre 91500-970, RS, Brazil.
| |
Collapse
|
123
|
Qiao N, Liu Q, Meng H, Zhao D. Haemolytic activity and adjuvant effect of soyasaponins and some of their derivatives on the immune responses to ovalbumin in mice. Int Immunopharmacol 2014; 18:333-9. [DOI: 10.1016/j.intimp.2013.12.017] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Revised: 12/13/2013] [Accepted: 12/15/2013] [Indexed: 11/30/2022]
|
124
|
Carbonetti S, Oliver BG, Glenn J, Stamatatos L, Sather DN. Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies. PLoS One 2014; 9:e86905. [PMID: 24466285 PMCID: PMC3900663 DOI: 10.1371/journal.pone.0086905] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2013] [Accepted: 12/15/2013] [Indexed: 11/17/2022] Open
Abstract
We evaluated four gp140 Envelope protein vaccine immunogens that were derived from an elite neutralizer, subject VC10042, whose plasma was able to potently neutralize a wide array of genetically distinct HIV-1 isolates. We sought to determine whether soluble Envelope proteins derived from the viruses circulating in VC10042 could be used as immunogens to elicit similar neutralizing antibody responses by vaccination. Each gp140 was tested in its trimeric and monomeric forms, and we evaluated two gp140 trimer vaccine regimens in which adjuvant was supplied at all four immunizations or at only the first two immunizations. Interestingly, all four Envelope immunogens elicited high titers of cross-reactive antibodies that recognize the variable regions V1V2 and are potentially similar to antibodies linked with a reduced risk of HIV-1 acquisition in the RV144 vaccine trial. Two of the four immunogens elicited neutralizing antibody responses that neutralized a wide array of HIV-1 isolates from across genetic clades, but those responses were of very low potency. There were no significant differences in the responses elicited by trimers or monomers, nor was there a significant difference between the two adjuvant regimens. Our study identified two promising Envelope immunogens that elicited anti-V1V2 antibodies and broad, but low potency, neutralizing antibody responses.
Collapse
Affiliation(s)
- Sara Carbonetti
- Seattle BioMed, Seattle, Washington, United States of America
| | - Brian G Oliver
- Seattle BioMed, Seattle, Washington, United States of America
| | - Jolene Glenn
- Seattle BioMed, Seattle, Washington, United States of America
| | - Leonidas Stamatatos
- Seattle BioMed, Seattle, Washington, United States of America ; Department of Global Health, University of Washington, Seattle, Washington, United States of America
| | - D Noah Sather
- Seattle BioMed, Seattle, Washington, United States of America
| |
Collapse
|
125
|
Gu G, An L, Fang M, Guo Z. Efficient one-pot synthesis of tigogenin saponins and their antitumor activities. Carbohydr Res 2014; 383:21-6. [PMID: 24239606 DOI: 10.1016/j.carres.2013.10.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2013] [Revised: 10/22/2013] [Accepted: 10/23/2013] [Indexed: 12/20/2022]
Abstract
An efficient synthesis of naturally occurring tigogenin triglycoside 1a and its three derivatives 1b-d bearing different carbohydrate moieties, as well as their antitumor activities, is described. Partially protected thiogalactosides bearing unprotected 2,4-OH or 4-OH groups were used to facilitate regioselective reactions for one-pot sequential multi-step glycosylation, which has significantly simplified the target molecule synthesis. The synthetic saponins 1a-d exhibited much higher anti-tumor activities than the positive control cisplatin against the human epithelial cervical cancer cell (HeLa) as evaluated by CCK-8 assay.
Collapse
Affiliation(s)
- Guofeng Gu
- National Glycoengineering Research Center, Shandong University, Jinan 250010, PR China.
| | - Lian An
- National Glycoengineering Research Center, Shandong University, Jinan 250010, PR China
| | - Min Fang
- National Glycoengineering Research Center, Shandong University, Jinan 250010, PR China
| | - Zhongwu Guo
- National Glycoengineering Research Center, Shandong University, Jinan 250010, PR China.
| |
Collapse
|
126
|
Wang P, Dai Q, Thogaripally P, Zhang P, Michalek SM. Synthesis of QS-21-based immunoadjuvants. J Org Chem 2013; 78:11525-34. [PMID: 24147602 DOI: 10.1021/jo402118j] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Three structurally defined QS-21-based immune adjuvant candidates (2a-2c) have been synthesized. Application of the two-stage activation glycosylation approach utilizing allyl glycoside building blocks improved the synthetic accessibility of the new adjuvants. The efficient synthesis and establishment of the stand-alone adjuvanticity of the examined synthetic adjuvant (2b) open the door to the pursuit of a new series of structurally defined QS-saponin-based synthetic adjuvants.
Collapse
Affiliation(s)
- Pengfei Wang
- Department of Chemistry, ‡Department of Pediatric Dentistry, and §Department of Microbiology, University of Alabama at Birmingham , 901 14th Street South, Birmingham, Alabama 35294, United States
| | | | | | | | | |
Collapse
|
127
|
Gu G, Zhao Y, Guo Z. Synthesis of Leonosides E and F derived from Leonurus japonicas Houtt. Carbohydr Res 2013; 380:174-80. [DOI: 10.1016/j.carres.2013.07.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2013] [Revised: 07/25/2013] [Accepted: 07/27/2013] [Indexed: 10/26/2022]
|
128
|
Abstract
The ever-increasing emergence of the resistance of mammalian tumor cells to chemotherapy and its severe side effects reduces the clinical efficacy of a large variety of anticancer agents that are currently in use. Thus, despite the significant progress in cancer therapeutics in the last decades, the need to discover and to develop new, alternative, or synergistic anticancer agents remains. Cancer prevention or chemotherapy based on bioactive fractions or pure components derived from desert plants with known cancer-inhibiting properties suggests promising alternatives to current cancer therapy. Plants growing on low nutrient soils and/or under harsh climatic conditions, such as extreme temperatures, intense solar radiation, and water scarcity, are particularly susceptible to attack from reactive oxygen species and have evolved efficient antioxidation defense systems. The many examples of desert plants displaying anticancer effects as presented here indicates that the same defensive secondary metabolites protecting them against the harsh environment may also play a protective or a curative role against cancer, as they also do against diabetes, neurodegenerative, and other acute and chronic diseases. The present review highlights a plethora of studies focused on the antineoplastic properties of desert plants and their prinicipal phytochemicals, such as saponins, flavonoids, tannins, and terpenes. Although many desert plants have been investigated for their antitumor properties, there are many that still remain to be explored - a challenge for the prospective cancer therapy of the future.
Collapse
|
129
|
Hao J, Liu J, Wen X, Sun H. Synthesis and cytotoxicity evaluation of oleanolic acid derivatives. Bioorg Med Chem Lett 2013; 23:2074-7. [PMID: 23434227 DOI: 10.1016/j.bmcl.2013.01.129] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Revised: 01/26/2013] [Accepted: 01/30/2013] [Indexed: 01/11/2023]
Abstract
Twelve derivatives of oleanolic acid (1) have been synthesized and evaluated for their inhibitory activities against the growth of prostate PC3, breast MCF-7, lung A549, and gastric BGC-823 cancer cells by MTT assays. Within these series of derivatives, compound 17 exhibited the most potent cytotoxicity against PC3 cell line (IC50=0.39 μM) and compound 28 displayed the best activity against A549 cell line (IC50=0.22 μM). SAR analysis indicates that H-donor substitution at C-3 position of oleanolic acid may be advantageous for improvement of cytotoxicity against PC3, A549 and MCF-7 cell lines.
Collapse
Affiliation(s)
- Jia Hao
- Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, PR China
| | | | | | | |
Collapse
|
130
|
Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies. Int J Pharm 2012; 441:636-42. [PMID: 23117021 DOI: 10.1016/j.ijpharm.2012.10.033] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2012] [Revised: 10/20/2012] [Accepted: 10/23/2012] [Indexed: 10/27/2022]
Abstract
Carrier mediated delivery of vaccines along with adjuvants can possibly address the issue related to oral vaccines like inadequate immune potentiation. In this study, chitosan functionalized gold nanoparticles (CsAuNPs) were used as a carrier for the model antigen tetanus toxoid (TT) along with immunostimulant Quillaja saponaria extract (QS). Physicochemical properties (size, zeta potential, pH value) of formulation were investigated as stability indicating parameters. The synthesized CsAuNPs were spherical in shape, around 40 nm in size, positively charged (around +35 mV) and had TT and QS payload of 65% and 0.01%, respectively. Formulation parameters did not alter the secondary structure of TT, as determined by FTIR, fluorescence and CD spectroscopy. Antigen specificity, determined by an ELISA, was also not compromised. The CsAuNPs conferred protection to TT against gastric hydrolysis as studied in vitro. TT-QS-CsAuNPs induced up to 28-fold immune responses compared to control formulations (TT, TT-QS) after oral administration of formulations in BALB/c mice. The immune responses were quantified by measuring the TT-specific IgG and IgA titers using ELISA. Findings herein demonstrate that co-delivery of TT and QS with functionalized CsAuNPs promotes better systemic and local immune responses and hence can be considered as a sound approach for oral vaccine delivery.
Collapse
Affiliation(s)
- Ganesh Barhate
- Bharati Vidyapeeth University, Poona College of Pharmacy, Department of Pharmaceutics, Erandwane, Pune 411038, India
| | | | | | | | | |
Collapse
|
131
|
Demberg T, Robert-Guroff M. Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol 2012; 3:250. [PMID: 22912636 PMCID: PMC3418522 DOI: 10.3389/fimmu.2012.00250] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2012] [Accepted: 07/27/2012] [Indexed: 12/21/2022] Open
Abstract
This review provides an overview of the current status of the global HIV pandemic and strategies to bring it under control. It updates numerous preventive approaches including behavioral interventions, male circumcision (MC), pre- and post-exposure prophylaxis (PREP and PEP), vaccines, and microbicides. The manuscript summarizes current anti-retroviral treatment options, their impact in the western world, and difficulties faced by emerging and resource-limited nations in providing and maintaining appropriate treatment regimens. Current clinical and pre-clinical approaches toward a cure for HIV are described, including new drug compounds that target viral reservoirs and gene therapy approaches aimed at altering susceptibility to HIV infection. Recent progress in vaccine development is summarized, including novel approaches and new discoveries.
Collapse
Affiliation(s)
- Thorsten Demberg
- Vaccine Branch, Section on Immune Biology of Retroviral Infection, National Cancer Institute, National Institutes of Health Bethesda, MD, USA
| | | |
Collapse
|
132
|
Chea EK, Fernández-Tejada A, Damani P, Adams MM, Gardner JR, Livingston PO, Ragupathi G, Gin DY. Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes. J Am Chem Soc 2012; 134:13448-57. [PMID: 22866694 DOI: 10.1021/ja305121q] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
QS-21 is a potent immunostimulatory saponin that is currently under clinical investigation as an adjuvant in various vaccines to treat infectious diseases, cancers, and cognitive disorders. Herein, we report the design, synthesis, and preclinical evaluation of simplified QS-21 congeners to define key structural features that are critical for adjuvant activity. Truncation of the linear tetrasaccharide domain revealed that a trisaccharide variant is equipotent to QS-21, while the corresponding disaccharide and monosaccharide congeners are more toxic and less potent, respectively. Modification of the acyl chain domain in the trisaccharide series revealed that a terminal carboxylic acid is well-tolerated while a terminal amine results in reduced adjuvant activity. Acylation of the terminal amine can, in some cases, restore adjuvant activity and enables the synthesis of fluorescently labeled QS-21 variants. Cellular studies with these probes revealed that, contrary to conventional wisdom, the most highly adjuvant active of these fluorescently labeled saponins does not simply associate with the plasma membrane, but rather is internalized by dendritic cells.
Collapse
Affiliation(s)
- Eric K Chea
- Pharmacology Program, Weill Cornell Graduate School of Medical Sciences, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
| | | | | | | | | | | | | | | |
Collapse
|
133
|
Abstract
INTRODUCTION Adjuvants potentiate immune responses, reducing the amount and dosing frequency of antigen required for inducing protective immunity. Adjuvants are of special importance when considering subunit, epitope-based or more unusual vaccine formulations lacking significant innate immunogenicity. While numerous adjuvants are known, only a few are licensed for human use; principally alum, and squalene-based oil-in-water adjuvants. Alum, the most commonly used, is suboptimal. There are many varieties of adjuvant: proteins, oligonucleotides, drug-like small molecules and liposome-based delivery systems with intrinsic adjuvant activity being perhaps the most prominent. AREAS COVERED This article focuses on small molecules acting as adjuvants, with the author reviewing their current status while highlighting their potential for systematic discovery and rational optimisation. Known small molecule adjuvants (SMAs) can be synthetically complex natural products, small oligonucleotides or drug-like synthetic molecules. The author provides examples of each class, discussing adjuvant mechanisms relevant to SMAs, and exploring the high-throughput discovery of SMAs. EXPERT OPINION SMAs, particularly synthetic drug-like adjuvants, are amenable to the plethora of drug-discovery techniques able to optimise the properties of biologically active small molecules. These range from laborious synthetic modifications to modern, rational, effort-efficient computational approaches, such as QSAR and structure-based drug design. In principal, any property or characteristic can thus be designed in or out of compounds, allowing us to tailor SMAs to specific biological functions, such as targeting specific cells or pathways, in turn affording the power to tailor SMAs to better address different diseases.
Collapse
Affiliation(s)
- Darren R Flower
- University of Aston, School of Life and Health Sciences, Aston Triangle, Birmingham, B4 7ET, UK.
| |
Collapse
|